Analysts See $-0.43 EPS for Proteon Therapeutics, Inc. (PRTO)

February 24, 2018 - By Migdalia James

 Analysts See $ 0.43 EPS for Proteon Therapeutics, Inc. (PRTO)
Investors sentiment increased to 1.14 in 2017 Q3. Its up 0.60, from 0.54 in 2017Q2. It is positive, as 3 investors sold Proteon Therapeutics, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 7.15 million shares or 0.11% more from 7.14 million shares in 2017Q2 were reported.
11,716 were accumulated by Virtu Llc. Mariner Wealth Limited Liability Co reported 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Abingworth Llp, United Kingdom-based fund reported 2.02 million shares. Vanguard Gru holds 208,434 shares. Counselors Incorporated, a Missouri-based fund reported 50,000 shares. Geode Cap Mngmt Ltd Com owns 34,613 shares. Morgan Stanley invested in 2 shares or 0% of the stock. Mpm Asset Management Ltd Llc invested 0.96% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Northern Tru has 13,993 shares for 0% of their portfolio. Dimensional Fund Limited Partnership accumulated 18,561 shares. Perceptive Advsr Limited Liability Company stated it has 334,116 shares. Royal Bank & Trust Of Canada invested in 0% or 3,375 shares. Acadian Asset Mngmt Limited Liability accumulated 6,990 shares. Raymond James Inc holds 16,302 shares. Deerfield reported 1.22 million shares.

Since December 15, 2017, it had 1 buy, and 0 insider sales for $22,560 activity.

Analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report $-0.43 EPS on March, 15.They anticipate $0.01 EPS change or 2.38 % from last quarter’s $-0.42 EPS. After having $-1.08 EPS previously, Proteon Therapeutics, Inc.’s analysts see -60.19 % EPS growth. The stock decreased 4.35% or $0.1 during the last trading session, reaching $2.2. About 22,023 shares traded. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has declined 80.63% since February 24, 2017 and is downtrending. It has underperformed by 97.33% the S&P500.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Ratings Coverage

Among 8 analysts covering Proteon Therapeutics (NASDAQ:PRTO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. Proteon Therapeutics had 18 analyst reports since November 11, 2015 according to SRatingsIntel. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. Raymond James initiated Proteon Therapeutics, Inc. (NASDAQ:PRTO) on Wednesday, November 11 with “Outperform” rating. Maxim Group maintained Proteon Therapeutics, Inc. (NASDAQ:PRTO) rating on Wednesday, December 14. Maxim Group has “Buy” rating and $6 target. The rating was initiated by Maxim Group with “Buy” on Thursday, November 10. The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) earned “Market Perform” rating by Cowen & Co on Wednesday, December 14. On Wednesday, December 14 the stock rating was downgraded by Raymond James to “Market Perform”. The firm has “Hold” rating given on Thursday, June 22 by Stifel Nicolaus. Stifel Nicolaus downgraded Proteon Therapeutics, Inc. (NASDAQ:PRTO) rating on Wednesday, December 14. Stifel Nicolaus has “Hold” rating and $3 target. The firm earned “Hold” rating on Wednesday, August 16 by Oppenheimer. On Wednesday, October 26 the stock rating was upgraded by Raymond James to “Strong Buy”.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $38.76 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

More notable recent Proteon Therapeutics, Inc. (NASDAQ:PRTO) news were published by: Globenewswire.com which released: “Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for …” on May 10, 2017, also Seekingalpha.com with their article: “Proteon Therapeutics: Hope For Kidney Failure Patients And Special-Situations …” published on July 06, 2017, Globenewswire.com published: “Proteon Therapeutics Announces Second Quarter 2017 Financial Results” on August 07, 2017. More interesting news about Proteon Therapeutics, Inc. (NASDAQ:PRTO) were released by: Seekingalpha.com and their article: “Have You Ever Heard Of Proteon Therapeutics?” published on July 19, 2016 as well as Globenewswire.com‘s news article titled: “Proteon Therapeutics Announces $22.0 Million Private Placement” with publication date: June 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: